GenMont Biotech Incorporation reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was TWD 95.49 million compared to TWD 99.48 million a year ago. Net income was TWD 11.72 million compared to TWD 14.75 million a year ago. Basic earnings per share from continuing operations was TWD 0.14 compared to TWD 0.17 a year ago. Diluted earnings per share from continuing operations was TWD 0.14 compared to TWD 0.17 a year ago.
For the six months, sales was TWD 186.45 million compared to TWD 203.24 million a year ago. Net income was TWD 35.02 million compared to TWD 45.36 million a year ago. Basic earnings per share from continuing operations was TWD 0.41 compared to TWD 0.53 a year ago. Diluted earnings per share from continuing operations was TWD 0.4 compared to TWD 0.52 a year ago.